Opportunity Information: Apply for PAR 06 213
Apply for PAR 06 213
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Clinical Trials Oral Complications of Cancer Therapy (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121 Oral Diseases and Disorders Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Mar 7, 2006.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Independent school districts Public and State controlled institutions of higher education For profit organizations other than small businesses Native American tribal governments (Federally recognized) City or township governments Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification) State governments County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government are eligible to apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PAR 06-213, titled "Clinical Trials Oral Complications of Cancer Therapy (R21)," is a discretionary grant program jointly supported by the National Institute of Dental and Craniofacial Research (NIDCR) and the National Cancer Institute (NCI). It focuses on clinical research aimed at reducing how often oral complications occur, and how severe they become, in patients receiving cancer treatment. In practical terms, the program is trying to move promising ideas closer to real-world use by supporting early-stage clinical studies that can show whether an intervention is feasible, safe, and potentially effective in preventing or managing mouth-related side effects of cancer therapies.
A central goal of this announcement is to fund what it calls "Clinical Pilot Data Grants." These are intended to generate preliminary clinical data strong enough to justify and design a later, larger Phase III clinical trial. That means the emphasis is not on completing a definitive, practice-changing trial right now, but on doing the kind of well-planned pilot work that makes a future Phase III trial realistic and competitive. Applicants would generally be expected to use the R21 mechanism to test methods, refine study procedures, evaluate recruitment and retention strategies, confirm the suitability of outcome measures, and produce early signals of clinical benefit (or identify barriers and limitations) in the context of oral complications from cancer therapy.
The funding instrument is a grant under the NIH R21 activity, and the listed award ceiling is $200,000. There is no cost sharing or matching requirement, which lowers the barrier for institutions that might not have discretionary funds to contribute. The opportunity sits within the health and education-related federal funding activity categories, and it is associated with CFDA numbers 93.121 (Oral Diseases and Disorders Research) and 93.395 (Cancer Treatment Research), reflecting its cross-cutting relevance to both oral health and oncology supportive care.
Eligibility is broad and includes many types of domestic organizations, such as public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities), state and local governments (including counties, cities or townships, special district governments, independent school districts, and public housing authorities), tribal governments and tribal organizations, and for-profit organizations other than small businesses. Importantly, the announcement also specifies that foreign institutions are eligible to apply, and eligible agencies of the U.S. Federal Government may also apply. This wide eligibility range suggests NIH wanted to encourage diverse clinical environments and research infrastructures, including settings that directly treat cancer patients and can realistically conduct clinical studies involving oral assessments and supportive care interventions.
The announcement was originally posted on March 7, 2006, and it indicates multiple receipt dates rather than a single deadline, meaning applications could be submitted at various standard NIH submission cycles during the active period of the program. The archive date is June 1, 2009, which signals that this particular FOA is no longer active, although its content still provides a useful template for how NIH frames pilot clinical trial work in this area. For full details, the original posting referenced an NIH guide link (http://grants.nih.gov/grants/guide/pa-files/PAR-06-213.html), and it provided NIH Office of Extramural Research (OER) webmaster contacts for access or linking issues.
Overall, this opportunity is best understood as targeted support for early clinical trials focused on the mouth-related toxicities of cancer treatment, with the explicit purpose of building the clinical evidence base and operational groundwork needed to launch a rigorous Phase III trial in the future.
FAQs: NIH PAR-06-213 - Clinical Trials Oral Complications of Cancer Therapy (R21)
What is PAR-06-213?
PAR-06-213 is an NIH funding opportunity titled "Clinical Trials Oral Complications of Cancer Therapy (R21)." It was a discretionary grant program jointly supported by the National Institute of Dental and Craniofacial Research (NIDCR) and the National Cancer Institute (NCI).
What is the main purpose of this funding opportunity?
The program supports clinical research aimed at reducing the frequency and severity of oral complications in patients receiving cancer treatment. It is designed to help move promising intervention ideas closer to real-world use by supporting early-stage clinical studies that can demonstrate feasibility, safety, and potential effectiveness for preventing or managing mouth-related side effects of cancer therapies.
What types of studies does this opportunity emphasize?
The announcement emphasizes early-stage clinical studies, particularly pilot clinical trial work intended to generate preliminary clinical data. The focus is on building evidence and operational readiness rather than completing a definitive, practice-changing trial at this stage.
What are "Clinical Pilot Data Grants" in the context of this FOA?
"Clinical Pilot Data Grants" are studies funded under this announcement to generate preliminary clinical data strong enough to justify and design a later, larger Phase III clinical trial. The idea is to produce pilot data and refine the approach so a future Phase III trial is realistic, well-designed, and competitive.
Is the goal to fund a full Phase III clinical trial?
No. The explicit emphasis is on pilot work that prepares for a later Phase III clinical trial. This includes planning and executing the type of preliminary clinical testing needed to support a larger, definitive study in the future.
What kinds of activities would an R21 project typically support under this FOA?
Applicants would generally be expected to use the R21 mechanism to test methods, refine study procedures, evaluate recruitment and retention strategies, confirm the suitability of outcome measures, and produce early signals of clinical benefit (or identify barriers and limitations) related to oral complications from cancer therapy.
What NIH grant mechanism is used for this opportunity?
This opportunity uses the NIH R21 activity, which is a grant mechanism commonly used for exploratory and developmental research, including early clinical work intended to establish feasibility and generate preliminary data.
What is the maximum award amount listed?
The listed award ceiling is $200,000.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
Which NIH institutes support this program?
The program is jointly supported by the National Institute of Dental and Craniofacial Research (NIDCR) and the National Cancer Institute (NCI).
What topic area does the funding fall under?
It is focused on oral complications related to cancer therapy, sitting at the intersection of oral health research and oncology supportive care, with a clinical trials emphasis.
What federal funding activity categories are associated with this opportunity?
The opportunity is associated with health and education-related federal funding activity categories.
What CFDA numbers are linked to this opportunity?
The opportunity is associated with CFDA 93.121 (Oral Diseases and Disorders Research) and CFDA 93.395 (Cancer Treatment Research).
Who is eligible to apply?
Eligibility is broad and includes many types of organizations, such as public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities), and a range of government entities.
Are nonprofit organizations eligible?
Yes. Both 501(c)(3) and non-501(c)(3) nonprofit organizations are listed as eligible.
Are for-profit organizations eligible?
Yes. For-profit organizations other than small businesses are listed as eligible.
Are state and local governments eligible?
Yes. The eligibility list includes state and local governments, including counties, cities or townships, special district governments, independent school districts, and public housing authorities.
Are tribal governments and tribal organizations eligible?
Yes. Tribal governments and tribal organizations are included in the eligibility list.
Are foreign institutions eligible to apply?
Yes. The announcement specifies that foreign institutions are eligible to apply.
Can U.S. Federal Government agencies apply?
Yes. Eligible agencies of the U.S. Federal Government may also apply.
Does the FOA have a single deadline?
No. It indicates multiple receipt dates rather than a single deadline, meaning applications could be submitted at various standard NIH submission cycles during the active period.
When was the opportunity originally posted?
The announcement was originally posted on March 7, 2006.
Is this funding opportunity still active?
No. The archive date is June 1, 2009, which signals that this particular funding opportunity is no longer active.
Where can the original funding announcement be found?
The original posting referenced an NIH guide link: http://grants.nih.gov/grants/guide/pa-files/PAR-06-213.html
Who is listed for technical or access-related help in the original posting?
The original posting provided NIH Office of Extramural Research (OER) webmaster contacts for access or linking issues.
What is the practical takeaway for applicants reading this FOA?
The key idea is targeted support for early clinical trial work on mouth-related toxicities of cancer treatment, with an explicit purpose of building preliminary evidence and the operational groundwork needed to launch a rigorous Phase III trial later.
Browse more opportunities from the same category: Education Health
Next opportunity: Cutting Edge Basic Research Awards (CEBRA) (R21)
Previous opportunity: NIDCR Small Research Grants for Data Analysis and Statistical Methodology (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 06 213
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 06 213) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cutting Edge Basic Research Awards (CEBRA) (R21) Apply for PAR 06 209 Funding Number: PAR 06 209 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Information Technologies and the Internet in Health Services and Intervention Delivery (R21) Apply for PA 06 224 Funding Number: PA 06 224 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Information Technologies and the Internet in Health Services and Intervention Delivery (R03) Apply for PA 06 225 Funding Number: PA 06 225 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Mechanisms of Alcohol Associated Cancers (R21) Apply for PA 06 270 Funding Number: PA 06 270 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Exploratory Grants for Behavioral Research in Cancer Control (R21) Apply for PA 06 351 Funding Number: PA 06 351 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Memory T Lymphocytes in Cancer Immunology (R21) Apply for PA 06 349 Funding Number: PA 06 349 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Building Translational Research in Integrative Behavioral Science (R21) Apply for PAR 06 355 Funding Number: PAR 06 355 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| In vivo Cancer Imaging Exploratory/Developmental Grants (R21) Apply for PA 06 371 Funding Number: PA 06 371 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Cancer Surveillance Using Health Claims based Data System (R21) Apply for PA 06 386 Funding Number: PA 06 386 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Developmental Projects in Complementary Approaches to Cancer Care (R21) Apply for PA 06 400 Funding Number: PA 06 400 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Studies of Energy Balance and Cancer in Humans (R21) Apply for PA 06 405 Funding Number: PA 06 405 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Phased Innovation Research in Cancer Prognosis and Prediction (R21/R33) Apply for PA 06 434 Funding Number: PA 06 434 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Phase II Developmental Research in Cancer Prognosis and Prediction (R33) Apply for PA 06 435 Funding Number: PA 06 435 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Development of Frontal Cortex and Limbic System and their roles in Drug Abuse or Mental Health (R21) Apply for PA 06 445 Funding Number: PA 06 445 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Drug Abuse Dissertation Research Epidemiology, Prevention, Treatment, Services, and Women and Sex/Gender Differences (R36) Apply for PAR 06 476 Funding Number: PAR 06 476 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Behavioral and Integrative Treatment Development Program (R21) Apply for PA 06 487 Funding Number: PA 06 487 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 06 488 Funding Number: PA 06 488 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Health Services Research on Practice Improvement Utilizing Community Treatment Programs within the National Drug Abuse Clinical Trials Network (CTN) (R21) Apply for PA 06 496 Funding Number: PA 06 496 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Health Services Research on Practice Improvement Utilizing Community Treatment Programs within the National Drug Abuse Clinical Trials Network (CTN) (R03) Apply for PA 06 497 Funding Number: PA 06 497 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Exfoliated Cells and Circulating DNA in Cancer Detection and Diagnosis(R21) Apply for PA 06 499 Funding Number: PA 06 499 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 06 213", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.